comparemela.com

Page 2 - Herapy Stem Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndromes

The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.

United statesServier pharmaceuticalsDrug administrationAbbott realtimeMyelodysplastic syndromeTransplantation stem cellRansplantation hematopoietic stem cellHematopoietic stem cell transplantationStem cell transplantationStem cell therapyHerapy stem cellBiologic therapyAcute leukemiaUs food and drug administrationNited states food and drug administrationHepatocellular carcinoma

Survival on the Upswing in Multiple Myeloma

Hematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed.

United statesTom brokawStanley katzRafael fonsecaJamesr berensonSteve scaliseLos angelesNational cancer instituteWinship cancer instituteAmerican society of hematologyEmory universityNational comprehensive cancer networkCaris life sciencesWest hollywoodSagar lonialWinship cancer

Salvage Option to Replace Transplant in RR Hodgkin Lymphoma?

A chemoimmunotherapy and radiation combination without autologous stem cell transplant produced high response rates in children and young adults with low-risk relapsed/refractory Hodgkin lymphoma.

United statesDana farber cancer instituteBrad hoppeBristol myers squibbChildren oncology groupAmerican society of radiation oncologyMayo clinicAmerican societyRadiation oncologyOncology groupEuronet paediatric hodgkin lymphomaHodgkins lymphomaMonoclonal antibodyTransplantation stem cellRansplantation hematopoietic stem cellHematopoietic stem cell transplantation

Telethon Foundation Will Make and Distribute ADA-SCID Drug

The initiative will ensure the availability of a drug that otherwise would have been abandoned as unprofitable.

Alessandro aiutiFrancesca pasinelliFoundation stepsNational health service for italianScientific institute for researchTelethon foundationSan raffaele telethon institute for gene therapyEuropean unionEuropean medicines agencyPediatric immunohematology unitScientific instituteSan raffaele hospitalSan raffaele telethon instituteGene therapyOrchard therapeuticsSan raffaele

FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma

The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.

Philip serlinDrug administrationMultiple myelomaPlasma cell myelomaTransplantation stem cellRansplantation hematopoietic stem cellHematopoietic stem cell transplantationStem cell transplantationStem cell therapyHerapy stem cellTransplantation cellularCellular transplantationUs food and drug administrationNited states food and drug administration

vimarsana © 2020. All Rights Reserved.